MedTrace Logo

Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia

NCT06637332 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2026-05-07

No results posted yet for this study

Summary

This is an open label randomized controlled trial for patients with methicillin resistant S. aureus (MRSA) bloodstream infection which will directly compare the two most commonly used therapies, vancomycin and daptomycin.

This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)

Conditions

  • Staphylococcus Aureus Septicemia
  • Staphylococcus Aureus Bacteremia
  • S. Aureus Bacteremia
  • S. Aureus Bloodstream Infection
  • Staphylococcus Aureus Endocarditis

Interventions

DRUG

Daptomycin for Injection

Daptomycin given by injection at a dose determined by the treating team but not to be less than 6mg/kg

DRUG

Vancomycin (IV)

Vancomycin by injection to be given at a dose selected by the treating team to achieve a desired trough level or AUC-based target, as determined by local standards of care

Sponsors & Collaborators

  • University of Melbourne

    collaborator OTHER

  • The Peter Doherty Institute for Infection and Immunity

    collaborator OTHER

  • Todd C. Lee MD MPH FIDSA

    lead OTHER

Principal Investigators

  • Todd C Lee, MD MPH FIDSA · McGill University Health Centre/Research Institute of the McGill University Health Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-14
Primary Completion
2027-01-31
Completion
2027-11-30

Countries

  • Australia
  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06637332 on ClinicalTrials.gov